Fig. 7

CircHAS2 as a predictive biomarker for response to anlotinib. A Schematic of the experimental setup for in vitro culture experiments involving PDO models. B Representative images of PDOs treated with the indicated concentrations of anlotinib via microscopy (scale bar: 10 μm). C The IC50 values of organoids treated with the indicated concentrations of anlotinib. D Schematic of the experimental setup for in vivo experiments involving PDX models. E Representative images and IHC scores of CRC PDX models were established and evaluated for circHAS2 expression by ISH staining. F Representative images of subcutaneous PDX tumors. The mice were given vehicle control and anlotinib, respectively. G The PDX tumors growth curve with measurements taken every two days. H The weights of subcutaneous PDX tumors were analyzed at the endpoint in each group. I Kaplan–Meier survival curves of the PDX models after the indicated treatments. Statistical significance in two-group experiments was evaluated using a two-sided Student’s t-test. Survival analysis was performed using the Log-rank method. Data are represented as mean ± SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, no significance